

Paul A Beavis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3408608/paul-a-beavis-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

5,046
citations

32
h-index

71
g-index

72
ext. papers

6,850
ext. citations

14.2
avg, IF

5.55
L-index

#	Paper	IF	Citations
61	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. <i>Clinical Cancer Research</i> , 2013 , 19, 5636-46	12.9	485
60	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018 , 24, 986-993	50.5	420
59	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. <i>Nature</i> , 2017 , 549, 101-105	50.4	375
58	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016 , 22, 1499-509	12.9	311
57	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 11091-6	11.5	303
56	CD73: a potent suppressor of antitumor immune responses. <i>Trends in Immunology</i> , 2012 , 33, 231-7	14.4	253
55	Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 14711-6	11.5	244
54	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses. <i>Cancer Immunology Research</i> , 2015 , 3, 506-17	12.5	198
53	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017 , 127, 929-941	15.9	183
52	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017 , 18, 2162-2174	10.6	170
51	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. <i>Cancer Cell</i> , 2019 , 36, 385-401.e8	24.3	169
50	CD73-deficient mice are resistant to carcinogenesis. <i>Cancer Research</i> , 2012 , 72, 2190-6	10.1	156
49	Immunosuppressive activities of adenosine in cancer. <i>Current Opinion in Pharmacology</i> , 2016 , 29, 7-16	5.1	156
48	Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2020 , 26, 487-504	12.9	138
47	Relevance of tumor-infiltrating lymphocytes in breast cancer. <i>BMC Medicine</i> , 2015 , 13, 202	11.4	131
46	Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E2068-E2076	11.5	129
45	Tumor immune evasion arises through loss of TNF sensitivity. <i>Science Immunology</i> , 2018 , 3,	28	119

44	Targeting Adenosine Receptor Signaling in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	90
43	Targeting the epigenetic regulation of antitumour immunity. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 776-800	64.1	81
42	Sex-specific adipose tissue imprinting of regulatory T cells. <i>Nature</i> , 2020 , 579, 581-585	50.4	72
41	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017 , 23, 2478-2490	12.9	71
40	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 341-348	19.4	70
39	Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	65
38	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. <i>Nature Communications</i> , 2017 , 8, 606	17.4	60
37	Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity. <i>Nature Immunology</i> , 2020 , 21, 914-926	19.1	53
36	CD3bright signals on T cells identify IL-17A-producing VβVα+ T cells. <i>Immunology and Cell Biology</i> , 2015 , 93, 198-212	5	50
35	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. <i>Cancer Research</i> , 2017 , 77, 1296-1309	10.1	46
34	Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 16717-22	11.5	43
33	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. <i>Seminars in Immunology</i> , 2016 , 28, 64-72	10.7	41
32	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. <i>Cancer Immunology Research</i> , 2018 , 6, 1069-1081	12.5	38
31	PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours. <i>EMBO Journal</i> , 2020 , 39, e103637	13	36
30	Antagonism of IAPs Enhances CAR T-cell Efficacy. <i>Cancer Immunology Research</i> , 2019 , 7, 183-192	12.5	33
29	CD73: A potential biomarker for anti-PD-1 therapy. <i>Oncotarget</i> , 2015 , 4, e1046675	7.2	23
28	CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. <i>Nature Communications</i> , 2021 , 12, 3236	17.4	22
27	IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors. <i>Molecular Therapy</i> , 2020 , 28, 2379-2393	11.7	19

26	Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion. <i>Cancer Research</i> , 2020 , 80, 4129-4144	10.1	19
25	Activation of p38 mitogen-activated protein kinase is critical step for acquisition of effector function in cytokine-activated T cells, but acts as a negative regulator in T cells activated through the T-cell receptor. <i>Immunology</i> , 2011 , 132, 104-10	7.8	18
24	Cellular networks controlling T cell persistence in adoptive cell therapy. <i>Nature Reviews Immunology</i> , 2021 , 21, 769-784	36.5	17
23	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. <i>Immunotherapy</i> , 2015 , 7, 499-512	3.8	16
22	A blockade enhances anti-metastatic immune responses. <i>Oncolimmunology</i> , 2013 , 2, e26705	7.2	13
21	Efficient CRISPR/Cas9 Gene Editing in Uncultured Naive Mouse T Cells for In Vivo Studies. <i>Journal of Immunology</i> , 2020 , 204, 2308-2315	5.3	12
20	CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory. <i>Cancer Discovery</i> , 2021 , 11, 2582-2601	24.4	12
19	Tissue-specific tumor microenvironments influence responses to immunotherapies. <i>Clinical and Translational Immunology</i> , 2019 , 8, e1094	6.8	11
18	Switching on the green light for chimeric antigen receptor T-cell therapy. <i>Clinical and Translational Immunology</i> , 2019 , 8, e1046	6.8	9
17	MAIT cells regulate NK cell-mediated tumor immunity. <i>Nature Communications</i> , 2021 , 12, 4746	17.4	8
16	Cross-talk between tumors can affect responses to therapy. <i>Oncolimmunology</i> , 2015 , 4, e975572	7.2	7
15	Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-6	7.1	5
14	The role of exhaustion in CAR T cell therapy. <i>Cancer Cell</i> , 2021 , 39, 885-888	24.3	5
13	Tumor-derived exosomes modulate T cell function through transfer of RNA. <i>FEBS Journal</i> , 2018 , 285, 1030-1032	5.7	4
12	A novel combination strategy for effectively targeting cancer stem-like cells. <i>Immunology and Cell Biology</i> , 2017 , 95, 573-574	5	3
11	Adoptive transfer of tumor-specific Th9 cells eradicates heterogeneous antigen-expressing tumor cells. <i>Cancer Cell</i> , 2021 ,	24.3	3
10	PTP1B is an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity. <i>Cancer Discovery</i> , 2021 ,	24.4	3
9	A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells. <i>Molecular Therapy</i> , 2017 , 25, 1997-1998	11.7	2

8	Myeloma natural killer cells are exhausted and have impaired regulation of activation. <i>Haematologica</i> , 2021 , 106, 2522-2526	6.6	2
7	T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. <i>OncImmunology</i> , 2017 , 7, e1365997	7.2	1
6	Pharmacological and genetic strategies for targeting adenosine to enhance adoptive T cell therapy of cancer. <i>Current Opinion in Pharmacology</i> , 2020 , 53, 91-97	5.1	1
5	p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy. <i>Cancer Cell</i> , 2020 , 37, 756-758	24.3	0
4	Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis. <i>Cancer Research</i> , 2021 , 81, 5803-5805	10.1	0
3	Differential location of NKT and MAIT cells within lymphoid tissue.. <i>Scientific Reports</i> , 2022 , 12, 4034	4.9	0
2	A New Safety Approach Allowing Reversible Control of CAR T Cell Responses. <i>Molecular Therapy</i> , 2020 , 28, 1563-1566	11.7	
1	Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200284	2.2	